Cytotoxicity News and Research

RSS

Bacteria-based cancer therapy achieves tumor eradication without immune cells

A joint research team led by Professor Eijiro Miyako of the Japan Advanced Institute of Science and Technology (JAIST), in collaboration with Daiichi Sankyo Co., Ltd. and University of Tsukuba, has developed a groundbreaking immune-independent bacterial cancer therapy using a novel microbial consortium called AUN.

5 Aug 2025

New radioimmunotherapy approach eliminates cancer stem cells in preclinical models of ovarian cancer

A new radioimmunotherapy approach has been shown to successfully eliminate cancer stem cells (CSCs) in preclinical models of ovarian cancer, outperforming the current gold standard.

1 Aug 2025

Bioengineered dressing achieves rapid hemostasis and accelerated wound healing

In a study published in Advanced Materials on July 22, a team led by Dr. ZHONG Chao and Dr. AN Bolin from the Shenzhen Institute of Advanced Technology of the Chinese Academy of Sciences, collaborating with Dr. LIU Yan from Ruijin Hospital Aﬃliated to Shanghai Jiao Tong University School of Medicine, developed an innovative bacterial cellulose (BC)-based hemostatic dressing that enables rapid and sustained bleeding control.

1 Aug 2025

Neutrophils emerge as key players in cancer progression and therapy

Neutrophils are the most abundant type of white blood cells, critical for immune defense and inflammation control.

28 Jul 2025

AI-designed proteins bring personalized cancer treatment within reach

Precision cancer treatment on a larger scale is moving closer after researchers have developed an AI platform that can tailor protein components and arm the patient's immune cells to fight cancer.

24 Jul 2025

Different anti-PD-L1 antibodies show varied results in tumor growth inhibition

Immune checkpoint inhibitors (ICIs), a powerful form of immunotherapy, have revolutionized cancer treatment by unleashing the body's own immune system to fight tumors.

24 Jul 2025

Optogenetic platform enables precise discovery of anti-aging therapeutics

A landmark study published in Cell has unveiled a first-of-a-kind optogenetic screening platform, developed by scientists at Integrated Biosciences, a biotechnology company integrating optogenetics, chemistry and AI to discover small molecule therapeutics for age-related diseases.

16 Jul 2025

Single-cell sequencing maps immune changes in chronic myeloid leukemia

Chronic myeloid leukemia (CML) is a hematopoietic malignancy characterized by BCR-ABL1 gene fusion.

9 Jul 2025

Nanohydrogel formulation of 5-fluorouracil shows promise for skin cancer therapy

Announcing a new article publication for BIO Integration journal. The pyrimidine analog 5-flurouracil (5-FU) is effective against solid tumors.

9 Jul 2025

Aromatic benzaldehyde inhibits growth of therapy-resistant pancreatic cancer

During therapy, some cancer cells evolve to escape elimination. Newer anticancer drugs that can overcome this resistance are necessary.

2 Jul 2025

Single-cell transcriptomes of immune cells offer insight into juvenile idiopathic arthritis

Juvenile idiopathic arthritis (JIA), a type of arthritis commonly occurring in children, is a chronic, inflammatory condition that affects the joints, causing pain, swelling, stiffness, and limiting the range of motion.

2 Jul 2025

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

Discover how 3D biology, automation, and AI are revolutionizing drug discovery, improving predictive accuracy, and accelerating research.

From Molecular Devices UK Ltd 12 Jun 2025

Navigating the dual role of B cells in tumor immunity

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

3 Jun 2025

Avelumab and cetuximab combination shows promise in phase II skin cancer trial

A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating that the combination of avelumab and cetuximab improved progression-free survival (PFS) compared to avelumab alone in patients with advanced cutaneous squamous cell carcinoma (cSCC).

1 Jun 2025

New glycopeptide antibiotic discovered to combat resistant bacteria

An international team of researchers, led by the University of Vienna and the Helmholtz Institute for Pharmaceutical Research Saarland, has discovered saarvienin A, a new type of glycopeptide antibiotic.

14 May 2025

New rifamycin drugs fight antibiotic-resistant lung infections more effectively

Researchers have developed next-generation rifamycin analogs that effectively kill both replicating and nonreplicating Mycobacterium abscessus while minimizing drug-drug interactions. Lead candidates UMN-120 and UMN-121 showed superior efficacy to current treatments in mouse models and retained potency against M. tuberculosis.

5 May 2025